Enhanced Nitric Oxide Delivery Through Self‐Assembling Nanoparticles for Eradicating Gram‐Negative Bacteria

In the current battle against antibiotic resistance, the resilience of Gram‐negative bacteria against traditional antibiotics is due not only to their protective outer membranes but also to mechanisms like efflux pumps and enzymatic degradation of drugs, underscores the urgent need for innovative antimicrobial tactics. Herein, this study presents an innovative method involving the synthesis of three furoxan derivatives engineered to self‐assemble into nitric oxide (NO) donor nanoparticles (FuNPs). These FuNPs, notably supplied together with polymyxin B (PMB), achieve markedly enhanced bactericidal efficacy against a wide spectrum of bacterial phenotypes at considerably lower NO concentrations (0.1–2.8 µg mL−1), which is at least ten times lower than the reported data for NO donors (≥200 µg mL−1). The bactericidal mechanism is elucidated using confocal, scanning, and transmission electron microscopy techniques. Neutron reflectometry confirms that FuNPs initiate membrane disruption by specifically engaging with the polysaccharides on bacterial surfaces, causing structural perturbations. Subsequently, PMB binds to lipid A on the outer membrane, enhancing permeability and resulting in a synergistic bactericidal action with FuNPs. This pioneering strategy underscores the utility of self‐assembly in NO delivery as a groundbreaking paradigm to circumvent traditional antibiotic resistance barriers, marking a significant leap forward in the development of next‐generation antimicrobial agents. This study presents an innovative approach to combat antibiotic‐resistant Gram‐negative bacteria by utilizing self‐assembling nanoparticles that deliver nitric oxide (NO). These nanoparticles, combined with polymyxin B, significantly enhance antibacterial efficacy at lower NO concentrations, disrupting bacterial membranes and reducing resistance development. The findings offer a promising pathway for next‐generation antimicrobial therapies.